DUSP26 and non-small cell lung carcinoma: Falnidamol combined with cisplatin was demonstrated to enhance the cytotoxicity of cisplatin and inhibit NSCLC cells’ proliferation by downregulating the expression of dual-specificity phosphatase 26 (DUSP26), leading to ferroptosis through free iron accumulation and lipid peroxidation [94].